3965 related articles for article (PubMed ID: 6354414)
1. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
[TBL] [Abstract][Full Text] [Related]
2. Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
Phillips GL; Wolff SN; Fay JW; Herzig RH; Lazarus HM; Schold C; Herzig GP
J Clin Oncol; 1986 May; 4(5):639-45. PubMed ID: 3009725
[TBL] [Abstract][Full Text] [Related]
3. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
Papadakis V; Dunkel IJ; Cramer LD; Kramer E; Papadopoulos E; Goldman S; Packer RJ; Willoughby M; Baker D; Garvin J; Strandjord S; Coccia P; Kaplan AM; Klemperer M; Finlay JL
Bone Marrow Transplant; 2000 Jul; 26(2):153-60. PubMed ID: 10918425
[TBL] [Abstract][Full Text] [Related]
4. Autologous bone-marrow transplantation: host effects of high-dose BCNU.
Takvorian T; Parker LM; Hochberg FH; Canellos GP
J Clin Oncol; 1983 Oct; 1(10):610-20. PubMed ID: 6366127
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy without autologous bone marrow transplantation in melanoma.
Tchekmedyian NS; Tait N; Van Echo D; Aisner J
J Clin Oncol; 1986 Dec; 4(12):1811-8. PubMed ID: 3537218
[TBL] [Abstract][Full Text] [Related]
6. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) autologous bone marrow transplantation therapy of refractory cancer: a preliminary report.
Phillips GL; Fay JW; Herzig GP; NaPombejara C; Wolff SN
Exp Hematol; 1979; 7 Suppl 5():372-83. PubMed ID: 400699
[TBL] [Abstract][Full Text] [Related]
7. High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.
Mortimer JE; Hewlett JS; Bay J; Livingston RB
J Neurooncol; 1983; 1(3):269-73. PubMed ID: 6088718
[TBL] [Abstract][Full Text] [Related]
8. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer.
Lazarus HM; Herzig RH; Graham-Pole J; Wolff SN; Phillips GL; Strandjord S; Hurd D; Forman W; Gordon EM; Coccia P
J Clin Oncol; 1983 Jun; 1(6):359-67. PubMed ID: 6366139
[TBL] [Abstract][Full Text] [Related]
9. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
Johnson DB; Thompson JM; Corwin JA; Mosley KR; Smith MT; de los Reyes RA; Daly MB; Petty AM; Lamaster D; Pierson WP
J Clin Oncol; 1987 May; 5(5):783-9. PubMed ID: 3553437
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
[TBL] [Abstract][Full Text] [Related]
11. Early pulmonary toxicity after administration of high-dose BCNU.
Litam JP; Dail DH; Spitzer G; Vellekoop L; Verma DS; Zander AR; Dicke KA
Cancer Treat Rep; 1981; 65(1-2):39-44. PubMed ID: 6261949
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
Lotz JP; Machover D; Malassagne B; Hingh B; Donsimoni R; Gumus Y; Gerota J; Lam Y; Tulliez M; Marsiglia H
J Clin Oncol; 1991 Oct; 9(10):1860-70. PubMed ID: 1919636
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
[TBL] [Abstract][Full Text] [Related]
15. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Attal M; Canal P; Schlaifer D; Chatelut E; Dezeuze A; Huguet F; Payen C; Pris J; Laurent G
J Clin Oncol; 1994 Jan; 12(1):141-8. PubMed ID: 8270970
[TBL] [Abstract][Full Text] [Related]
16. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
Adams DM; Zhou T; Berg SL; Bernstein M; Neville K; Blaney SM;
Pediatr Blood Cancer; 2008 Mar; 50(3):549-53. PubMed ID: 17941066
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
[TBL] [Abstract][Full Text] [Related]
19. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
Jones RB; Matthes S; Shpall EJ; Fisher JH; Stemmer SM; Dufton C; Stephens JK; Bearman SI
J Natl Cancer Inst; 1993 Apr; 85(8):640-7. PubMed ID: 8468721
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinoma.
Presant CA; Hillinger S; Klahr C
Cancer; 1980 Jan; 45(1):6-10. PubMed ID: 6243243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
